Frank Holler, CEO and Partner

Frank Holler is an active investor and successful entrepreneur. He previously served as President & CEO of Xenon Pharmaceuticals Inc., a private genomics-based drug development company, from 1999 to 2003; President & CEO of ID Biomedical Corporation, a vaccine development company sold to GlaxoSmithKline plc, from 1991 to 1998; and a founding director of Angiotech Pharmaceuticals, a TSX/ NASDAQ listed biotechnology company, from 1992 to 1997. Prior to working in biotechnology and healthcare, Mr. Holler was a Vice-President of Investment Banking with Merrill Lynch Canada and Wood Gundy Inc. (now CIBC World Markets).

Frank presently serves on the board of directors of BC Advantage Funds (Chairman), Protox Therapeutics Inc. (Chairman), Allon Therapeutics Inc., Aquinox Pharmaceuticals Inc., Genome British Columbia, the Prevention of Organ Failure Centre of Excellence (PROOF); Providence Healthcare and Xenon Pharmaceuticals Inc.  He was previously a Director of the British Columbia Biotechnology Association from 1992 to 1998 and, in 2003, received the BC Biotech Award for Vision and Leadership.

Frank holds a Masters of Business Administration degree and Bachelor of Arts (Economics) degree from the University of British Columbia.